RETATRUTIDE·DISTRICT OF COLUMBIA·LAST CHECKED 1 NOV 2026
Is Retatrutide legal in District of Columbia?
CAVEATS APPLY
We found no District of Columbia statute, board rule or enforcement action that names Retatrutide, so federal law applies. Not as a drug. Retatrutide has no FDA approval, so selling it for human use breaks federal drug law, and a 'research use only' label does not protect a seller whose site signals human use. It is not a controlled substance, and possessing it is not a federal crime. Pharmacies cannot compound it.
CATEGORY · INVESTIGATIONAL
Full status breakdown
FEDERAL · STATE · SPORT-BODYFederal status
FDA approval
DEA scheduling
not scheduled
503A compounding
FDA interim category: Not in any FDA category
503A Bulks List: not on list
Not eligible. Retatrutide has no FDA approval, no USP monograph and is not on the 503A Bulks List; FDA warning letters state it cannot be lawfully compounded. Ohio's Board of Pharmacy names it as a research-use-only drug its inspectors find in clinics.
FDA Warning Letters
- Dec 10, 2024 — Summit Research Peptides (cited: retatrutide, tirzepatide) · LETTER ↗
- Dec 10, 2024 — Xcel Research LLC (cited: retatrutide, cagrilintide, mazdutide) · LETTER ↗
- Sep 9, 2025 — GLP-1 Solution (cited: retatrutide) · LETTER ↗
- Mar 31, 2026 — Gram Peptides (cited: retatrutide, tirzepatide) · LETTER ↗
- Mar 31, 2026 — Prime Sciences (cited: retatrutide) · LETTER ↗
Shortage status
not currently on shortage list
Sale framing
Research-use-only posture: FDA has consistently rejected 'research use only' labeling as a safe harbor when site evidence (dosing instructions, vials/syringes, comparisons to weight-loss drugs) shows human-use intent. Multiple Warning Letters cite this exact pattern for retatrutide.
Personal possession: Personal possession of unapproved investigational peptides sits in a regulatory gray zone. FDA enforcement focus has been on vendor-side marketing and sale, not buyer-side possession, but no formal safe harbor exists.
District of Columbia — state-specific
Sport-body status
WADA 2026
prohibited · class S0 · in and out of competition
Not named, and GLP-1 agonists as a class are not on the 2026 List. Retatrutide falls under S0 because no government has approved it. WADA's 2027 List, in force from 1 Jan 2027, now names 'peptides' among the S0 examples; the status does not change.
USADA
banned
NCAA
unknown
What we couldn’t verify
Also known as
7 ALIASESRetatrutide is also marketed or referenced under the following names (vendor pseudonyms, brand names, chemical identifiers):
LY3437943GLP-3triple-GGGG triple agonistGLP-1/GIP/glucagon triple agonistRETAR-10mg
Related
FOLLOW-ONS- Are peptides legal in the US? — all 44 compounds in one table
- Retatrutide research guide — mechanism, published research, public lab records
- Peptide pricing index — what each compound costs per mg across audited vendors
- Janoshik COA verifier — a separate question from legality: does the COA the vendor cites actually exist?
Retatrutide: US status, sources and what changed
Other states with a rule that names Retatrutide: Ohio, California. Everywhere else, federal law applies.